IGC Pharma aligns fiscal year with calendar year

IGC Pharma (IGC) announced that its Board of Directors has approved a change in the Company’s fiscal year end from March 31 to December 31, effective December 31, 2025. “This is a straightforward but important step in strengthening how we engage with U.S. investors,” said Ram Mukunda, CEO of IGC Pharma. “Aligning our fiscal year with the calendar year improves clarity, comparability, and accessibility of our financial reporting. As we continue advancing our clinical and AI-driven programs, we want our reporting structure to reflect the standards and expectations of the U.S. public markets.” As a result of this change, IGC Pharma will file a transition report on Form 10-K with the U.S. Securities and Exchange Commission covering the nine-month period from April 1, 2025, through December 31, 2025. Beginning in 2026, the Company will report financial results on a calendar-year basis.